| Intrinsic Valuation of: AUROPHARMA | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 60 | Market Cap | ₹878B | |||||
| 2021 | - | - (-) | P/E Ratio | 25 | Total Asset | ₹498B | |||||
| 2022 | ₹23B | - (-) | Net Income | ₹35B | Total Debt | ₹16B | |||||
| 2023 | ₹-3B | -114.4% (-113.7%) | EBITDA | ₹71B | Total Liab | ₹171B | |||||
| 2024 | ₹-11B | -237.8% (-189.7%) | Opr Margin | 16.09 | Debt/Equity | 0.05 | |||||
| 2025 | ₹14B | 224.7% (214.1%) | PreTax Margin | 14.68 | BV/Share | 489 | |||||
| 5Y Average FCF | ₹6B | 3.5% (-29.8%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.04% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (3.5%) | ||||||||||
| 2026 | ₹16B | MBG Intrinsic Value | ₹537 | ||||||||
| 2027 | ₹16B | ||||||||||
| 2028 | ₹17B | ||||||||||
| 2029 | ₹17B | ||||||||||
| 2030 | ₹18B | ||||||||||
| 2031 | ₹18B | ||||||||||
| Terminal Value | ₹413B | Net Worth/Share | ₹562 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹356B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹56B | ₹682 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹16B | WACC | 6.5% | 650 | 701 | 764 | 846 | 955 | |||
| Equity Value | ₹396B | 7.1% | 585 | 623 | 670 | 728 | 802 | ||||
| Shares Outstanding | 580,801,623 | 7.8% | 532 | 562 | 597 | 640 | 693 | ||||
| 8.4% | 489 | 513 | 541 | 574 | 614 | ||||||
| DCF Intrinsic Value | ₹682 | 9.0% | 453 | 473 | 495 | 521 | 551 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||